AMGN34 Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.81 |
| 52 Week High | US$74.50 |
| 52 Week Low | US$45.12 |
| Beta | 0.60 |
| 11 Month Change | -11.29% |
| 3 Month Change | -10.30% |
| 1 Year Change | 26.20% |
| 33 Year Change | 42.85% |
| 5 Year Change | 61.07% |
| Change since IPO | 855.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -3.7% | -5.5% | 0.3% |
| 1Y | 26.2% | 8.9% | -1.7% |
Return vs Industry: AMGN34 exceeded the BR Biotechs industry which returned 8% over the past year.
Return vs Market: AMGN34 exceeded the BR Market which returned -1.6% over the past year.
Price Volatility
| AMGN34 volatility | |
|---|---|
| AMGN34 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.3% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: AMGN34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: AMGN34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| AMGN34 fundamental statistics | |
|---|---|
| Market cap | R$868.79b |
| Earnings (TTM) | R$24.42b |
| Revenue (TTM) | R$187.83b |
36.6x
P/E Ratio4.8x
P/S RatioIs AMGN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGN34 income statement (TTM) | |
|---|---|
| Revenue | US$32.53b |
| Cost of Revenue | US$12.82b |
| Gross Profit | US$19.71b |
| Other Expenses | US$15.48b |
| Earnings | US$4.23b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.87 |
| Gross Margin | 60.59% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 802.4% |
How did AMGN34 perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield113%
Payout RatioDoes AMGN34 pay a reliable dividends?
See AMGN34 dividend history and benchmarks| Amgen dividend dates | |
|---|---|
| Ex Dividend Date | Nov 14 2024 |
| Dividend Pay Date | Dec 13 2024 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 21 days |
Does AMGN34 pay a reliable dividends?
See AMGN34 dividend history and benchmarks